Literature DB >> 28893772

Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients.

Clara E Negri1, Sarah S Gonçalves2, Ana Cristina P Sousa1, Maria Daniela Bergamasco1, Marinês D V Martino3, Flavio Queiroz-Telles4, Valerio Rodrigues Aquino5, Paulo de Tarso O Castro6, Ferry Hagen7, Jacques F Meis7,8, Arnaldo L Colombo9.   

Abstract

Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  A. fumigatus; Brazil; antifungal resistance; invasive aspergillosis; triazole resistance

Mesh：

Substances：

Year:  2017        PMID： 28893772      PMCID： PMC5655068          DOI： 10.1128/AAC.00608-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

1.  Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.

Authors:  Paul E Verweij; Debbie T A Te Dorsthorst; Anthonius J M M Rijs; Hilly G De Vries-Hospers; Jacques F G M Meis
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

Review 2.  Pulmonary aspergillosis: recent advances.

Authors:  George R Thompson; Thomas F Patterson
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

Review 3.  Clinical implications of globally emerging azole resistance in Aspergillus fumigatus.

Authors:  Jacques F Meis; Anuradha Chowdhary; Johanna L Rhodes; Matthew C Fisher; Paul E Verweij
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-12-05       Impact factor: 6.237

4.  First itraconazole resistant Aspergillus fumigatus clinical isolate harbouring a G54E substitution in Cyp51Ap in South America.

Authors:  Florencia Leonardelli; Laura Theill; María Elena Nardin; Daiana Macedo; Catiana Dudiuk; Emilce Mendez; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Rev Iberoam Micol       Date:  2017-01-10       Impact factor: 1.044

5.  Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene.

Authors:  Shawn R Lockhart; João P Frade; Kizee A Etienne; Michael A Pfaller; Daniel J Diekema; S Arunmozhi Balajee
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

6.  Multi-triazole-resistant Aspergillus fumigatus infections in Australia.

Authors:  Sarah E Kidd; Emma Goeman; Jacques F Meis; Monica A Slavin; Paul E Verweij
Journal:  Mycoses       Date:  2015-04-17       Impact factor: 4.377

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 8.  Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Jianping Xu; Jacques F Meis
Journal:  PLoS Pathog       Date:  2013-10-24       Impact factor: 6.823

9.  Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia.

Authors:  Carlos Alvarez-Moreno; Rose-Anne Lavergne; Ferry Hagen; Florent Morio; Jacques F Meis; Patrice Le Pape
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883
View more
  3 in total

1.  Aspergillus fumigatus Clinical Isolates Carrying CYP51A with TR34/L98H/S297T/F495I Substitutions Detected after Four-Year Retrospective Azole Resistance Screening in Brazil.

Authors:  Laís Pontes; Caio Augusto Gualtieri Beraquet; Teppei Arai; Guilherme Leite Pigolli; Luzia Lyra; Akira Watanabe; Maria Luiza Moretti; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 2.  Emergence of Triazole Resistance in Aspergillus spp. in Latin America.

Authors:  Daiana Macedo; Florencia Leonardelli; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Curr Fungal Infect Rep       Date:  2021-05-19

3.  In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil.

Authors:  Laura Bedin Denardi; Bianca Hoch Dalla-Lana; Francielli Pantella Kunz de Jesus; Cecília Bittencourt Severo; Janio Morais Santurio; Régis Adriel Zanette; Sydney Hartz Alves
Journal:  Braz J Infect Dis       Date:  2017-11-22       Impact factor: 3.257
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.